Patent Eligibility For AI-Assisted Synthetic Biology And Bioengineering Innovations.

17 Feb 2026 --
0 Comments

1. Introduction: Patent Eligibility in Biotechnology & AI Context

Patent law in most jurisdictions (like the US, Europe, and India) requires an invention to satisfy three basic criteria:

Novelty – the invention must be new.

Inventive Step / Non-Obviousness – it must not be obvious to someone skilled in the art.

Patentable Subject Matter – it must fall within the scope of patent-eligible inventions.

In AI-assisted synthetic biology and bioengineering, the main challenge is patent eligibility, especially regarding:

Natural products or genes (which are generally non-patentable if naturally occurring).

Algorithms (AI software is often treated as an abstract idea).

Combination of AI with biotech processes, where courts ask whether the AI merely automates known biology or contributes something inventive.

2. Key US Legal Principles

In the United States, patent eligibility is governed by 35 U.S.C. §101, interpreted through Supreme Court rulings:

Mayo Collaborative Services v. Prometheus (2012)

Association for Molecular Pathology v. Myriad Genetics (2013)

Alice Corp. v. CLS Bank (2014)

These cases are central when assessing AI-biotech inventions.

Case 1: Mayo Collaborative Services v. Prometheus (2012)

Facts: Prometheus held patents on a method of adjusting drug doses based on metabolite levels.

Issue: Is a method that applies a natural law patentable?

Ruling: Supreme Court held it was not patentable because it claimed a natural law (the correlation between metabolite levels and drug effectiveness) merely applying routine steps.

Principle:

Natural laws, natural phenomena, and abstract ideas are not patentable.

Application must involve something “significantly more” than the natural law.

Implication for AI-Synthetic Biology:

AI models predicting gene editing outcomes or metabolic pathways cannot be patented just for predicting natural outcomes. They must involve a concrete, inventive application.

Case 2: Association for Molecular Pathology v. Myriad Genetics (2013)

Facts: Myriad patented isolated DNA sequences of BRCA1 and BRCA2 genes.

Issue: Are naturally occurring DNA sequences patentable?

Ruling: Supreme Court held that naturally occurring DNA sequences are not patentable, but complementary DNA (cDNA), which is synthetically created, can be patented.

Principle:

Products of nature are excluded.

Man-made, human-engineered sequences are patentable.

Implication for AI-Synthetic Biology:

If AI generates novel synthetic genes or proteins not found in nature, these may be patentable.

AI assistance does not disqualify eligibility as long as the result is human-directed innovation.

Case 3: Alice Corp. v. CLS Bank (2014)

Facts: Alice Corp. held patents on a computer-implemented method for mitigating settlement risk in financial transactions.

Issue: Are computer-implemented inventions patentable?

Ruling: The Court applied a two-step test:

Determine if the claims are directed to an abstract idea.

If yes, see if the claim adds an “inventive concept” that transforms it into patent-eligible subject matter.

Principle: Simply implementing an abstract idea on a computer is not enough.

Implication for AI-Synthetic Biology:

AI algorithms used in synthetic biology (e.g., protein folding prediction, metabolic pathway optimization) cannot be patented in isolation.

Patent eligibility improves if the AI algorithm is tied to a concrete biological process or invention.

Case 4: Diamond v. Chakrabarty (1980)

Facts: Chakrabarty genetically engineered a bacterium that could digest crude oil.

Issue: Is a genetically modified organism patentable?

Ruling: Yes, because it was not naturally occurring and had markedly different characteristics from any found in nature.

Principle:

Living organisms modified by humans can be patented.

Patent eligibility extends to synthetic biology innovations if there’s human intervention creating something new.

Implication for AI-Synthetic Biology:

AI-designed microbes, enzymes, or synthetic circuits that are novel and human-directed can be patented.

Case 5: In re Roslin Institute (Dolly the Sheep) (2006, Federal Circuit)

Facts: Dolly the sheep was cloned from an adult sheep cell. Patents were sought on the cloned animal.

Issue: Are clones of animals patentable?

Ruling: No, because the cloned sheep was not markedly different from the naturally occurring sheep, and the process merely replicated nature.

Principle:

Patent eligibility requires human-directed innovation creating a new and distinct entity, not merely copying nature.

Implication for AI-Synthetic Biology:

AI-assisted cloning or gene-editing methods need to produce truly inventive organisms or products, not mere copies of natural systems.

Case 6: Harvard College v. Canada (Commissioner of Patents) [2002] (Canadian Case)

Facts: Harvard patented on genetically modified mice (“oncomice”) for cancer research.

Ruling: Patent was allowed because the mice had distinct characteristics due to human intervention.

Principle: Synthetic biological inventions are patentable when they show novelty and human ingenuity, not just natural traits.

Implication:

Internationally, courts support patenting AI-generated synthetic biology if it leads to novel, non-obvious organisms or biomolecules.

3. Practical Considerations for AI-Assisted Bioengineering Patents

Focus on Patentable Subject Matter:

AI code itself is abstract.

AI outputs that alter biology in a concrete, inventive way can be patented.

Document Human Contribution:

Courts require evidence that human inventors directed the AI to create something new.

Emphasize Novelty & Non-Obviousness:

AI may assist, but the invention must be novel, non-obvious, and useful.

Draft Claims Carefully:

Claims should cover biological entities, processes, and applications rather than just AI algorithms.

4. Summary Table of Case Principles

Case	Year	Principle	Implication for AI-Synthetic Biology
Mayo v. Prometheus	2012	Natural laws not patentable	AI predictions of natural phenomena need inventive application
Myriad Genetics	2013	Natural DNA not patentable, cDNA patentable	AI-designed synthetic genes can be patented
Alice Corp	2014	Abstract ideas need inventive concept	AI software alone not patentable; tie to concrete bio invention
Diamond v. Chakrabarty	1980	Genetically modified organisms patentable	AI-designed engineered microbes/proteins patentable
In re Roslin Institute	2006	Cloning not enough; needs marked difference	AI cloning requires inventive modification
Harvard College v. Canada	2002	Novel bio creations patentable	Supports AI-directed synthetic organism patents